INTRODUCTION
Chronic lymphocytic leukemia (CLL) is characterized by remarkable skewing of the B-cell receptor immunoglobulin (BcR IG) repertoire, culminating in the existence of subsets of patients with quasi-identical, stereotyped BcR IGs. This implies antigen selection in the natural history of CLL, ultimately affecting clonal behavior and clinical outcome. Indeed, immunogenetic characteristics of the clonal BcR IGs serve as established disease prognostic markers, typically exemplified by the subdivision of CLL cases into those with no or limited somatic hypermutation within the clonotypic immunoglobulins (IGs; 'unmutated' U-CLL), who generally experience an aggressive disease course versus those with a significant somatic hypermutation load within their IG genes ('mutated', M-CLL) who display a considerably more indolent disease. [1] [2] [3] Furthermore, certain stereotyped CLL subsets are associated with either aggressive (that is, subset #1 and subset #2) or indolent clinical course (that is, subset #4). 2, [4] [5] [6] This immunogenetic evidence for antigen involvement in CLL pathogenesis has been recently complemented by clinical evidence, where drugs inhibiting key elements of BcR signaling have proven highly efficacious, leading to their accelerated approval for the treatment of patients with CLL. [7] [8] [9] [10] Extracellular cues that are vital for CLL cell survival and proliferation are also provided by accessory cells, which, together with cytokines and chemokines, form the tumor microenvironment. 11 T cells appear to be a critical component of this microenvironment, as evidenced by animal model experiments demonstrating that CLL cell engraftment and clonal expansion depend on trophic signals provided by autologous T cells. 12 However, despite accumulating evidence of an intricate crosstalk between T cells and CLL B cells, [13] [14] [15] little is known regarding the role of antigen(s) in the selection and activation of cognate T cells. This is highly relevant in light of CLL and T cell interactions inducing T-cell tolerance, especially since reversal of this tolerance by immunomodulating drugs acting at the level of the immune synapse between clonal B and T cells shows promising results in clinical trials. [16] [17] [18] Using low-throughput subcloning techniques followed by Sanger sequencing in 58 CLL patients, we recently reported T-cell receptor beta chain (TRB) gene repertoire restriction, pointing to antigenic selection. 19 However, due to the inherent limitations of low-throughput analysis, definitive conclusions were not possible. Here, we sought to advance the analytical depth of our approach by employing high-throughput, next generation sequencing (NGS). Our analysis was intentionally biased toward patients expressing stereotyped BcR IGs, therefore cases most evidently selected by antigen. Additionally, we included M-CLL and U-CLL cases not assigned to stereotyped subsets in order to obtain a comprehensive view of the T-cell repertoire in CLL.
We report pronounced T-cell oligoclonality, with clonotypes that persist and expand over time and shared clonotypes between 1 different patients, especially those belonging to stereotyped subsets, which appear to be disease-specific. These findings implicate selection by antigenic elements that may be acting in a CLL subset-specific context. Whether these are the same antigens interacting with the malignant clone or tumor-derived antigens remains to be elucidated.
METHODS

Patient group
We analysed 57 samples from 32 untreated CLL patients (Supplementary  Table 1) , and two control samples from two healthy individuals (ages 70 and 80 year-old). 24 of the 32 CLL cases were selected based on their expression of stereotyped BcR IGs, which assigned them to well-annotated CLL subsets. More specifically, these cases belonged to subset #4 (n = 12), subset #1 (n = 8), and subset #2 (n = 4; Supplementary Table 2 ). The remaining eight CLL cases were not assigned to stereotyped subsets, carrying either mutated (o 98% IGHV identity to germline, n = 5) or truly unmutated (100% IGHV identity to germline, n = 3) BcR IGs. Two subset #4 and one subset #2 case were analysed over time (two timepoints, median sampling interval 23 months-all patients remained untreated throughout the sampling period). No case had evidence of infection (neither signs nor symptoms) at sampling. The great majority of CLL patients were cytomegalovirus and epstein-barr virus (EBV) seropositive, and so were both healthy individuals (Supplementary Table 3 ). The local Ethics Review Committee approved the study and written informed consent form was obtained from all individuals.
PCR amplification of TRBV-TRBD-TRBJ gene rearrangements and library preparation
Total cellular RNA was primarily isolated from peripheral blood mononuclear cells (n = 40), but also purified CD4 + and CD8 + T-cell subpopulations (n = 9 and n = 7, respectively), bone marrow (n = 2) or fresh lymph node (LN) tissue (n = 1). Isolation of CD4 + and CD8 + T-cell subpopulations was performed by negative selection (RosetteSep Human CD4 + /CD8 + T-Cell Enrichment Cocktail, Stemcell Technologies, Vancouver, Canada), resulting in 495% purity by flow cytometry. In all samples, starting absolute T-cell count exceeded 0.5 × 10 6 cells, in order to determine actual repertoire diversity instead of over-amplifying the same TRBV-TRBD-TRBJ rearrangements. For repertoire analyses, each category of samples was studied separately (PBMCs, BM, LN, CD4 + and CD8 + T cells). Except for two samples for which gradient RNA quantities were tested, in all other samples 1 μg of RNA was reverse transcribed to complementary DNA (cDNA) using the SuperScript II RT kit (Invitrogen Life technologies, Thermo Fisher Scientific, Waltham, MA, USA). TRBV-TRBD-TRBJ gene rearrangements were RT-PCR amplified according to the BIOMED-2 collaborative protocol. 20 Amplicons were gel-purified with the QIAGEN DNA purification columns (QIAGEN, Hilden, Germany) and used for library preparation (TruSeq LT, Illumina) according to the manufacturer's instructions. PhiX was used at a 20% concentration to optimize library diversity. Four runs were performed on the Illumina platform using the MiSeq Reagent Kit v2 (2 × 250 bp; Illumina Inc., San Diego, CA, USA).
Paired-end protocol allowed sequencing of the TRB complementaritydetermining region 3 (CDR3) twice/read, thus increasing the accuracy of results. Still, considering the inherent limitations of PCR-based NGS, the experimental setup included multiple internal controls: (i) 'sample replicates', that is, starting from aliquots of a single peripheral blood sample containing the same as well as varying T-cell counts (two duplicates and one quadruplicate, range 0.5-18 × 10 6 T cells), (ii) 'PCR replicates', that is, starting from the same RNA sample [two duplicates and one quadruplicate, containing the same as well as varying RNA quantity (range 1.0-5.8 μg)], and, (iii) 'sequencing replicates', that is, starting from the same PCR product but sequenced in separate MiSeq runs (five duplicates).
Bioinformatics processing of raw data, definitions and interpretation Initial data filtering was performed by the Illumina signal-processing software, leading to the rejection of low quality and erroneous sequences. Sequences were assigned to samples based on incorporated indexes, and sequence segments corresponding to the adapters were trimmed. In order to further increase the accuracy of results, raw NGS reads were subjected to a purpose-built, bioinformatics algorithm performing: (i) length and quality filtering of raw reads, (ii) merging of filtered-in paired reads via local alignment, (iii) length and quality filtering of stitched sequences. Detailed length, quality and overlap rules that were applied for the analysis are provided in Supplementary Table 4 .
Filtered-in sequences were submitted to IMGT/HighV-QUEST tool (http:// www.imgt.org), and metadata was processed by an in-house bioinformatics pipeline designed for clonotype computation and repertoire analysis. Only productive TRBV-TRBD-TRBJ gene rearrangements were included in the analysis. TRBV-TRBD-TRBJ gene rearrangements carrying TRBV genes with o95% germline identity were also discarded as sequences with unacceptable error rate, given the lack of somatic hypermutation in T cells.
Clonotypes were computed as unique pairs of TRBV genes and CDR3 amino acid sequences within a sample. Clonotypes were considered expanded (forming clusters) when they contained ⩾ 2 sequences, with the ten most expanded clonotypes within a sample referred to as major, otherwise they were considered as 'singletons'. The relative frequency of each clonotype/sample was calculated as the number of rearrangements corresponding to the clonotype divided by the total number of productive, filtered-in rearrangements for that particular sample. For repertoire analysis, clonotypes rather than single rearrangements were considered in order to avoid potential biases due to expansion following antigenic stimulation, that is, individual TRBV gene frequencies within a sample were calculated as the number of clonotypes using particular TRBV genes over the total number of clonotypes.
Comparison to healthy controls and public data mining
We performed clonotype comparison across all 32 CLL patients, as well as against the two healthy controls. Clonotypes from replicate samples as well as CD4
+ and CD8 + T-cell clonotypes belonging to the same patient were concatenated, so that all clonotypes of each patient would be included in the comparison. The 10 most expanded clonotypes of each CLL sample, referred to as 'major clonotypes', were compared to all clonotypes of the healthy controls (n = 248 593), as well as a panel of 6318 non-redundant, well-annotated, unique clonotypes from various entities, available to our group (n = 2316) or retrieved from the IMGT/LIGM-DB sequence database (http://www.imgt.org/IMGTindex/LGM.html; n = 4002).
HLA typing
Typing of the HLA-A, -B, -C loci for low resolution and HLA-DRB1 locus for allelic level high-resolution determination was performed as described previously. 19 
Statistical analysis and visualization tools
Descriptive statistics for discrete parameters included counts and frequency distributions. For quantitative variables, statistical measures included means, medians, and min-max values. The significance of bivariate/multivariate relationships between variables was assessed using the unpaired t-test, and the non-parametric Kruskal Wallis and MannWhitney tests. Cox-regression and hazard ratio tests were applied for assessing the predictive value of T-cell clonality regarding time-to-firsttreatment. Time-to-first-treatment was evaluated from the sampling date until the date of initial treatment; untreated cases were censored at the time of last follow-up. For all comparisons a significance level of P = 0.05 was set. All statistical analyses were performed using the statistical Package GraphPad Prism version 5.03 (GraphPad Software, Inc., San Diego, CA, USA).
Data access
Raw TR sequence data discussed can be found under accession number SRR3737053 in GenBank sequence database (www.ncbi.nlm.nih.gov/gen bank/).
RESULTS
The T-cell repertoire of CLL is skewed, especially in CD8 + T cells Only six genes [TRBV12-3/12-4 (8.4%), TRBV29-1 (6.9%), TRBV27 (6.7%), TRBV19 (6.2%), TRBV7-9 (5.4%), and TRBV6-5 (5.1%)] accounted for more than one-third of the repertoire. No significant TRBV gene repertoire differences were identified between U-CLL versus M-CLL or amongst different stereotyped subsets. Of note, the frequency of individual TRBV genes differed significantly, when comparing the CLL CD8 + versus CD4 + T-cell repertoire. In particular, the TRBV27 and TRBV7-9 genes predominated in CD8 + versus CD4
+ T cells (6.4 versus 3.9%, P = 0.001 and 4.6 versus 2.6%, P = 0.001, respectively), whereas the opposite held for the TRBV5-1 and TRBV7-2 genes (4.0 versus 6.8%, P = 0.001 and 3.1 versus 6.0%, P = 0.002, respectively; Supplementary Table 5) .
Asymmetric TRBV gene usage characterized healthy samples as well, although the small number of samples analysed precludes comprehensive healthy TRBV gene repertoire analysis (Supplementary Table 7 ). However, the CLL TRB repertoire was significantly more oligoclonal compared to healthy controls as reflected in a median cumulative frequency of the 10 most expanded clonotypes/ sample of 23.6% in CLL versus 5.1% in healthy controls (Po0.05; Figure 1a ; Supplementary Table 8 ).
To investigate whether T-cell clonality is associated to disease course, we evaluated time-to-first-treatment in 22/24 CLL patients for whom PBMC samples were tested (measured from the date of sampling, when T-cell clonality was assessed, until the date of treatment or last follow-up date for untreated patients). The cumulative frequency of the 10 most expanded clonotypes/ patient did not reach statistical significance as an independent predictor for time-to-first-treatment when treated as a quantitative variable (P = 0.54). When we divided our patients into two clonality categories, above (n = 11) or below (n = 11) the median cumulative frequency of the 10 most expanded clonotypes (22.3%), we found that the former category was associated with higher probability for treatment need, albeit without reaching statistical significance (Hazard ratio 1.7, P = 0.34).
The distinct CLL immunogenetic subgroups analysed did not exhibit major differences regarding oligoclonality. Clonality stemmed mainly from the CD8 + T-cell compartment, where the median cumulative frequency of the 10 most expanded clonotypes/sample was 43.6% versus only 5.3% for the CD4 + T-cell samples, respectively (Po0.001; Figure 1b, Supplementary Table 8 ).
Longitudinal analysis reveals clonal persistence To assess clonal dynamics over time, one subset #2 and two subset #4 CLL patients were studied longitudinally, in two successive time points (median sampling interval 23 months). For the patient assigned to subset #2, PBMCs were analysed in both time points. The TRBV gene repertoire remained remarkably stable overtime (Figure 2a ). For the two subset #4 patients, the first time point involved PBMC analysis, whereas the second time point involved analysis of isolated CD4 + and CD8 + T-cell subpopulations, therefore TRBV gene repertoire comparison was not performed.
Major clonotypes (that is, the 10 most expanded clonotypes/ sample) were found to persist in all three studied cases. In the subset #2 case, 10.4% (3970/38054) of all clonotypes and 17.4% (2286/ 13134) of all expanded clonotypes from the first time point persisted over time. Interestingly, in the second time point the persisting clonotypes constituted a larger fraction of the total repertoire (31.9% of all clonotypes and 40.9% of all expanded clonotypes, respectively). In the two subset #4 patients, 14.9% (2576/17250) and 27.6% (9918/35962) of all clonotypes identified in the PBMC samples were found in subsequent time points (11.8 and 21.0% retained in the CD4 + T-cell compartment, and 3.1 and 6.6% retained in the CD8 + T-cell compartment, respectively). Similarly, 16.7% (1247/7455) and 35.3% (4984/14125) of all expanded clonotypes identified in the PBMC samples persisted in the following time points (13.1 and 26.8% retained in the CD4 + T-cell compartment, and 3.6 and 8.5% retained in the CD8 + T-cell compartment, respectively). Most major persisting clonotypes were contained within the CD8 + T-cell subpopulation (Figure 2b ). Shared T-cell receptor clonotypes in CLL: mostly disease-specific Comparisons across CLL patients and against the two healthy controls revealed that 162 179/2 464 321 (6.6%) CLL clonotypes were shared by two or more patients, 96.8% of which were not found in either healthy control. Most (79.2%) public CLL clonotypes concerned pairs of patients, and few were found in 3 (13.3%) or ⩾ 4 (7.5%) CLL patients. No pattern of similar disease characteristics was discerned among patients sharing clonotypes. Highly similar results were obtained, when performing the same analysis excluding singletons (data not shown).
In most cases, public CLL clonotypes were low-frequent. Hence, we performed the same analyses considering only the major clonotypes of each CLL sample and found: (i) two major clonotypes shared among two pairs of subset #4 patients, (ii) one major clonotype shared among a pair of subset #1 patients, (iii) one major clonotype shared among a subset #1 and a subset #2 patient, and, (iv) two major clonotypes shared among CLL patients belonging to different immunogenetic subgroups (that is, subset and non-subset cases); one of these was identified in healthy controls, albeit at very low frequencies (0.04 and 0.0005%, respectively). In all subset cases sharing major clonotypes, HLA typing revealed relevant HLA restrictions (Table 1,  Supplementary Table 9) .
We next performed cross-entity comparisons among the identified CLL major clonotypes and a panel of 6318 nonredundant, unique clonotypes from various entities deposited in the IMGT/LIGM-DB sequence database or available to our group. As shown in Table 1 , only a single public major CLL clonotype matched with a public database entry, corresponding to a T-large granular lymphocytic leukemia patient. This clonotype was not subset-specific, but rather shared between a subset #4 patient and a M-CLL patient not assigned to any stereotyped subset. Among the patient-specific ('private') CLL major clonotypes, we found matches with: (i) two EBV-specific clonotypes, (ii) a T-cell clonotype identified in a T-LGL patient, and, (iii) a T-cell clonotype from an individual with CLL-like monoclonal B-cell lymphocytosis, a condition considered as premalignant to CLL. Additionally, we found a match between a CD4 + T-cell clonotype belonging to a subset #1 patient (P17) with a T-cell clonotype from another subset #1 CLL patient previously analysed by our group through classic subcloning and Sanger sequencing ( Table 2) : this pair of subset #1 patients shared the HLA-DRB*13:03 allele. Hence, overall, public clonotypes shared between different CLL cases were mostly disease-specific, that is, not found amongst other entities.
Clonotype sharing in different tissue microenvironments For one subset #1 patient, synchronous peripheral blood and LN samples were tested. The TRBV gene repertoire was almost identical in both samples (Figure 3a) . The extent of clonality was also similar. In particular, the median cumulative frequency of the 10 most expanded clonotypes/sample was 8.8% in PBMCs versus 7.3% in the LN and the percentage of expanded clonotypes over the total repertoire of each sample was 37.2% (15072/40503) versus 38.1% (15639/41010), respectively. Overall, 18.7% (7576-/40503) clonotypes and 24.5% (3696/15072) expanded clonotypes identified in the PBMC sample were also identified in the LN sample, including two of the major clonotypes that were common for both tissue samples (Figure 3b ).
Replicates First, we examined 'sample replicates' that is, used aliquots of peripheral blood containing varying numbers of T cells (one quadruplicate and two duplicates). Overall, despite limited fluctuation of the TRBV gene repertoire, the dominant T-cell clonotypes showed remarkable consistency for the tested T-cell range (0.5-18 × 10 6 cells), proving that sample quantity ensured adequate repertoire profiling depth (Supplementary Figure 1) .
We then examined 'PCR replicates', that is, starting from the same RNA sample (one quadruplicate and two duplicates), containing varying RNA quantity. Again, limited fluctuations of the TRBV gene repertoire were noted in few instances, however the dominant T-cell clonotypes were practically identical, ensuring that both cDNA and NGS library preparation protocols are robust, at least for the RNA range tested (1.0-5.8 μg; Supplementary  Figure 3) .
Finally, we examined 'sequencing replicates', that is, starting from the same PCR product but sequenced in separate MiSeq runs, and actually different MiSeq machines (five duplicates). Both the TRBV gene repertoire and the dominant clonotypes were remarkably consistent, proving that the sequencing procedure is indeed reproducible (Supplementary Figure 5) . DISCUSSION NGS immunoprofiling holds the potential to reveal the architecture of complex repertoires, however still presents limitations and pitfalls. For the present analysis of the TRB repertoire in CLL, we followed a systematic and stringent approach including multiple controls, and focused on CLL cases assigned to the most populated and best-characterized CLL stereotyped subsets representing distinct entities with opposite clinical course and outcome. 2 We also included CLL patients carrying non-subset BcR IG rearrangements investigating whether certain T-cell immunogenetic features may be ubiquitous in CLL, regardless of the particular IG receptor that is expressed.
Our findings provide solid evidence for T-cell oligoclonality in all CLL patients analysed, stemming mainly from the CD8 + T-cells. A similar extent of TR oligoclonality was noted between patients with distinct BcR IG, thus sharply contrasting the polyclonal profile of age-matched healthy controls, suggestive of antigenic selection. That said, the TRBV gene frequency distribution did not differ significantly between CLL patients and healthy controls, prompting speculations that it might reflect either differential primer amplification efficacies or naturally occurring preferential TRBV gene rearrangements. 21, 22 Nevertheless, the statistically significant differences observed between CD4 + versus CD8 + TRBV gene repertoire favor the latter scenario.
A major finding of the present study concerned clonal persistence over time in CLL patients belonging to different immunogenetic subgroups of the disease (that is, subsets #2 and #4). Importantly, the persisting clonotypes, found within both the CD4 + and CD8 + T-cell compartments, constituted a larger fraction of the total repertoire in subsequent time points in all tested cases. Most major persisting clonotypes corresponded to CD8 + T-cells, however this might be attributed to the greater extent of clonality in the CD8 + T-cell repertoire. On these grounds, it is reasonable to argue that the selecting antigens are also persistent, driving the respective T-cell clones to further expansion. Despite the small number of samples analysed, clonal persistence was evident in two distinct immunogenetic subgroups of the disease with sharp clinicobiological differences (that is, subsets #2 and #4), thereby alluding to a generic CLL characteristic. It would be interesting to test this hypothesis in more CLL samples, including cases that are not assigned to any stereotyped subset. That said, ongoing interactions with the selecting antigen(s) emerge as a recurring theme in CLL pathobiology, being evident in both the clonotypic IGs (most notably in subset #4) [23] [24] [25] [26] and the TRs of the reactive T cells.
As expected for individuals who are not HLA-matched, most of the identified clonotypes were patient-specific ('private') and only few were 'public', that is, shared by ⩾ 2 patients. Moreover, most 'public' clonotypes were represented at low frequencies, therefore had dubious biological significance. However, and perhaps of most biological relevance, we also identified major clonotypes shared between different patients. These public major clonotypes tended to cluster among pairs of patients assigned to the same stereotyped subset, where the CLL cells are most likely selected by shared antigenic elements. 27, 28 Interestingly, they were not identified in the examined healthy controls, despite both expressing HLA-A*24, that is, fulfilling the identified HLA restriction for at least one major clonotype shared among two subset #1 patients. Overall, the aforementioned findings allude to selection of the T-cell repertoire by restricted antigenic epitopes in a subsetspecific context. Thus, they raise the possibility that the implicated antigens might be those selecting the CLL progenitors or even the malignant cells themselves. Alternatively, they could correspond to CLL subset-specific IG structures acting as idiotypic neoantigens. 29 Recent work combining crystallographic and functional studies provided exciting novel results regarding the epitopes involved in homotypic CLL BcR interactions. Such epitopes appear to indeed be subset-specific, thus elucidating the structural basis of autonomous activation of CLL B-cells and reconciling the existence of a shared pathogenetic mechanism with the distinct clinicobiological profiles of CLL subsets. 30 In light of these findings, these subset-specific epitopes could be tested as to whether they might be recognized/bound by cognate T cells. If successful, such endeavors will assist in clarifying the nature of antigenic elements that are responsible for T-cell repertoire skewing in CLL.
In conclusion, massive parallel sequencing documents the pronounced skewing of the TR repertoire in CLL, supporting selection by restricted antigenic elements. These elements appear to persist over time, driving the respective T-cell clones to further expansion. Expanded clonotypes are shared among patients, most especially among those assigned to the same stereotyped subset. Whether they recognize the same antigens interacting with the malignant clone or tumor-associated epitopes, possibly contained within the idiotypic IG, remains to be elucidated and may be of particular benefit in light of the clinical testing of immune checkpoint inhibitors, designed to boost endogenous T-cell antitumor responses. 18, 31, 32 
